Eli Lilly and Company (NYSE:LLY - Get Free Report) was down 0.5% during trading on Tuesday . The company traded as low as $744.52 and last traded at $746.85. Approximately 571,816 shares traded hands during trading, a decline of 81% from the average daily volume of 3,058,198 shares. The stock had previously closed at $750.77.
Wall Street Analyst Weigh In
A number of research analysts have commented on LLY shares. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. Truist Financial reiterated a "buy" rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. TheStreet upgraded shares of Eli Lilly and Company from a "c+" rating to a "b" rating in a research note on Friday, March 8th. Citigroup increased their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a "buy" rating in a report on Tuesday, April 2nd. Finally, BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $728.05.
Read Our Latest Research Report on LLY
Eli Lilly and Company Price Performance
The business's 50-day simple moving average is $762.68 and its 200 day simple moving average is $655.54. The company has a market capitalization of $709.35 billion, a P/E ratio of 128.34, a P/E/G ratio of 1.65 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts' expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm's quarterly revenue was up 28.1% compared to the same quarter last year. During the same period last year, the company posted $2.09 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 12.46 EPS for the current year.
Insider Buying and Selling at Eli Lilly and Company
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.13% of the company's stock.
Institutional Trading of Eli Lilly and Company
Institutional investors have recently added to or reduced their stakes in the business. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Core Wealth Advisors Inc. lifted its stake in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company's stock worth $29,000 after buying an additional 32 shares during the last quarter. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter worth $27,000. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $29,000. Finally, Retirement Group LLC lifted its stake in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company's stock worth $27,000 after buying an additional 35 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
